First-line lorlatinib achieves durable systemic and intracranial response in EML4-ALK positive large-cell neuroendocrine carcinoma: a case report with DNA/RNA fusion discordance

Background Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is the current first-line standard of care for advanced non-small cell lung cancer (NSCLC) harboring EML4-ALK rearrangement. However, ALK rearrangements are rarely identified in pulmonary large-cell neuroendocrine carcinoma (LCNEC), and clinical evidence supporting ALK TKI directed therapy in this population remains limited. Case presentation We report a 35-year-old man diagnosed with advanced large-cell neuroendocrine carcinoma (LCNEC) carrying an EML4-ALK rearrangement. First-line lorlatinib resulted in rapid systemic tumor regression and complete intracranial response. At the data cutoff, the patient's progression-free survival had not been reached at 13.47 months with good tolerability. DNA-based next-generation sequencing identified two ALK rearrangements, whereas RNA-based sequencing detected only the canonical EML4-ALK rearrangement transcript. Testicular pain occurred during treatment and improved after dose modification; however, a definitive causal relationship could not be established. Conclusion This case report demonstrates the efficacy of lorlatinib as first-line therapy for large-cell neuroendocrine carcinoma with ALK rearrangement. The observed DNA/RNA fusion discordance also illustrates the complementary roles of DNA- and RNA-based testing in interpreting complex genomic rearrangements.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-18
DOI
https://doi.org/10.3389/fmed.2026.1944174
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

First-line lorlatinib achieves durable systemic and intracranial response in EML4-ALK positive large-cell neuroendocrine carcinoma: a case report with DNA/RNA fusion discordance

Qiangzhong Pi, Peiqiang Liang, Hu Luo
2 links
Frontiers in Medicine
Lung Cancer Treatments and Mutations
article

First-line lorlatinib achieves durable systemic and intracranial response in EML4-ALK positive large-cell neuroendocrine carcinoma: a case report with DNA/RNA fusion discordance

Qiangzhong Pi, Peiqiang Liang, Hu Luo
article en

Abstract

Background Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is the current first-line standard of care for advanced non-small cell lung cancer (NSCLC) harboring EML4-ALK rearrangement. However, ALK rearrangements are rarely identified in pulmonary large-cell neuroendocrine carcinoma (LCNEC), and clinical evidence supporting ALK TKI directed therapy in this population remains limited. Case presentation We report a 35-year-old man diagnosed with advanced large-cell neuroendocrine carcinoma (LCNEC) carrying an EML4-ALK rearrangement. First-line lorlatinib resulted in rapid systemic tumor regression and complete intracranial response. At the data cutoff, the patient's progression-free survival had not been reached at 13.47 months with good tolerability. DNA-based next-generation sequencing identified two ALK rearrangements, whereas RNA-based sequencing detected only the canonical EML4-ALK rearrangement transcript. Testicular pain occurred during treatment and improved after dose modification; however, a definitive causal relationship could not be established. Conclusion This case report demonstrates the efficacy of lorlatinib as first-line therapy for large-cell neuroendocrine carcinoma with ALK rearrangement. The observed DNA/RNA fusion discordance also illustrates the complementary roles of DNA- and RNA-based testing in interpreting complex genomic rearrangements.

Frontiers in MedicineVol. 13
Army Medical University (CN), Southwest Hospital (CN)
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon